Showing 1-10 of 10 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Personalized antigen-specific immunotherapy to halt autoimmunity in pre-symptomatic and symptomatic Type 1 Diabetic subjects | Fondazione Centro San Raffaele | Silvia Gregori | Cures | 01-October-2021 to 31-October-2025 | $558,289.62 |
| Soluble PD-1: bringing to light an ignored player in Type 1 Diabetes progression. | National Research Council of Italy (IEOS-CNR) | Sara Bruzzaniti | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Implementation on the LIAISON® platform of T1D autoantibody immunoassays | Ospedale San Raffaele | Vito Lampasona | Cures | 01-October-2022 to 30-September-2025 | $432,142.46 |
| Unveiling the Relationship Between Insulin Resistance and Anti-Islet Immunity in T1D | Università degli Studi di Milano | Alessandra Petrelli | Cures | 01-January-2025 to 31-December-2025 | $110,000.00 |
| Disentangling circulating non-coding RNAs complexity by tracking their expression and origin in Type 1 Diabetes (DISCO-T1D) | Università degli Studi di Siena | Guido Sebastiani | Cures | 01-March-2025 to 28-February-2030 | $998,400.00 |
| Bio-engineering of a Vascularized Islet Organ (BioVIO) for the treatment of T1D | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-April-2022 to 30-September-2025 | $1,227,217.01 |
| Impact of NK cells on the outcome of transplantation in patients with Type 1 Diabetes | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-January-2023 to 31-December-2026 | $699,918.00 |
| Ladarixin and Antithymocyte Globulin (ATG) in New Onset Type1 Diabetes | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-February-2025 to 31-January-2028 | $996,691.00 |
| Late pre-clinical validation of safety and long-term functionality of hypoimmunogenic iPSC-derived β cells into fully humanized transgenic mouse model of Type 1 Diabetes. | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-December-2024 to 30-November-2027 | $999,995.70 |
| GLUT1 Inhibition in type 1 diabetes | Università Vita-Salute San Raffaele | Paolo Monti | Cures | 01-August-2024 to 30-April-2026 | $68,102.00 |